Prevalence of colistin and tigecycline resistance in Acinetobacter baumannii clinical isolates from 2 hospitals in Riyadh Region over a 2-year period

Saudi Medical Journal

Volumn 34, Issue 3, 2013, Pages 248-353

  Baadani, Abeer M ^a   Thawadi, Sahar I ^b   El Khizzi, Noura A ^a   Omrani, Ali S ^a  

^a The General Directorate of Armed Forces Health Services   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; BLOOD; CONFIDENTIALITY; ETHICS; HOSPITAL; HUMAN; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; MORPHOLOGY; NONHUMAN; PREVALENCE; RESPIRATORY SYSTEM; RETROSPECTIVE STUDY; REVIEW; URINE; WOUND;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; PREVALENCE; RETROSPECTIVE STUDIES; SAUDI ARABIA;

EID: 84875035592     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Schreckenberger P, Daneshvar M, Hollis D. Acinetobacter, Achromobacter, Chryseobacterium, Moraxella and other nonfermentative gram-negative rods. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, editors. Manual of clinical microbiology. 9th ed. Washington (DC): ASM Press; 2007. p. 770-802.
2. Fournier PE, Richet H, Weinstein RA. The Epidemiology and Control of Acinetobacter baumannii in Health Care Facilities. Clin Infect Dis 2006; 42: 692-699.
3. Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 2005; 11: 22-29.
4. Lolans K, Rice TW, Munoz-Price LS, Quinn JP. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 2006; 50: 2941-2945.
5. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG. Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42: 657-668.
6. Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 2004: 38: 1449-1459.
7. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12: 826-836.
8. TYGACIL® (tigecycline) For injection for intravenous use. [Updated: 2011; Accessed 2012 December 2). Available from URL: http://labeling.pfizer.com/showlabeling.aspx?id=491
9. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, et al. Colistin therapy for microbiologically documented multidrug-resistant Gramnegative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010; 35: 194-199.
10. Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009; 63: 775-780.
11. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008; 62: 45-55.
12. Metan G, Alp E, Yildiz O, Percin D, Aygen B, Sumerkan B. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections. J Chemother 2010; 22: 110-114.
13. Michalopoulos AS, Karatza DC. Multidrug-resistant Gramnegative infections: the use of colistin. Expert Rev Anti Infect Ther 2010; 8: 1009-1017.
14. Vila J, Pachon J. Therapeutic options for Acinetobacter baumannii infections. Expert Opin Pharmacother 2008: 9: 587-599.
15. Iredell J, Thomas L, Power D, Mendes E. Tigecycline resistance in Australian antibiotic-resistant Gram-negative bacteria. J Antimicrob Chemother 2007; 59: 816-818.
16. Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007; 27: 1198-1201.
17. Rodriguez CH, Bombicino K, Granados G, Nastro M, Vay C, Famiglietti A. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis 2009; 65: 188-191.
18. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 59: 772-774.
19. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et al. Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50: 2946-2950.
20. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. CLSI document M100-S22. Wayne (PA): Clinical and Laboratory Standards Institute; 2012.
21. Al-Sweih NA, Al-Hubail MA, Rotimi VO. Emergence of tigecycline and colistin resistance in Acinetobacter species isolated from patients in Kuwait hospitals. J Chemother 2011 23: 4.
22. Lee YT, Huang LY, Chiang DH, Chen CP, Chen TL, Wang FD, et al. Differences in phenotypic and genotypic characteristics among imipenem-non-susceptible Acinetobacter isolates belonging to different genomic species in Taiwan. Int J Antimicrob Agents 2009; 34: 580-584.
23. Tan TY, Ng LS. Susceptibility of multi-resistant gram-negative bacilli in Singapore to tigecycline as tested by agar dilution. Ann Acad Med Singapore 2007; 36: 4.
24. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 2007; 60: 1163-1167.
25. Peleg AY, Adams J, Paterson DL. Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 2065-2069.
26. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001; 39: 183-190.
27. Gilad J, Giladi M, Poch F, Aharoni Y, Schwartz D. "All-inone-plate" E-test and disk diffusion susceptibility co-testing for multiresistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 2006; 25: 799-802.
28. Kulah C, Celebi G, Aktas E, Mengeloglu Z, Comert F, Ankarali H. Unexpected tigecycline resistance among Acinetobacter baumannii Isolates: high minor error rate by Etest. J Chemother 2009; 21: 390-395.
29. Veenemans J, Mouton JW, Kluytmans JAJW, Donnely R, Verhulst C, van Keulen P. Effect of manganese in test media on in vitro bacterial susceptibility to tigecycline of Enterobacteriaceae and Acinetobacter baumannii to Tigecycline. J Clin Microbiol 2012; 50: 3077-3079.
30. Casal M, Rodriguez F, Johnson B, Garduno E, Tubau F, de Lejarazu RO, et al. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-nonsusceptible Acinetobacter spp. J Antimicrob Chemother 2009; 64: 69-72.
31. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters (Version 2.0). 2012 [Updated 2012 January 1; Cited 2012 July 2]. Available from URL: http://www.eucast. org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_ tables/Breakpoint_table_v_2.0_120221.pdf